JP2023509336A5 - - Google Patents

Info

Publication number
JP2023509336A5
JP2023509336A5 JP2022535637A JP2022535637A JP2023509336A5 JP 2023509336 A5 JP2023509336 A5 JP 2023509336A5 JP 2022535637 A JP2022535637 A JP 2022535637A JP 2022535637 A JP2022535637 A JP 2022535637A JP 2023509336 A5 JP2023509336 A5 JP 2023509336A5
Authority
JP
Japan
Prior art keywords
composition
use described
neovascularization
disorder
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022535637A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023509336A (ja
JP7730816B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2020/086993 external-priority patent/WO2021123142A1/en
Publication of JP2023509336A publication Critical patent/JP2023509336A/ja
Publication of JP2023509336A5 publication Critical patent/JP2023509336A5/ja
Application granted granted Critical
Publication of JP7730816B2 publication Critical patent/JP7730816B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022535637A 2019-12-19 2020-12-18 過剰血管新生に関連する眼疾患を治療する化合物 Active JP7730816B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP19218062 2019-12-19
EP19218062.8 2019-12-19
EP20156158.6 2020-02-07
EP20156158 2020-02-07
PCT/EP2020/086993 WO2021123142A1 (en) 2019-12-19 2020-12-18 Compounds for treatment of eye diseases associated with excessive vascularisation

Publications (3)

Publication Number Publication Date
JP2023509336A JP2023509336A (ja) 2023-03-08
JP2023509336A5 true JP2023509336A5 (cg-RX-API-DMAC7.html) 2023-12-26
JP7730816B2 JP7730816B2 (ja) 2025-08-28

Family

ID=74141502

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022535637A Active JP7730816B2 (ja) 2019-12-19 2020-12-18 過剰血管新生に関連する眼疾患を治療する化合物

Country Status (14)

Country Link
US (2) US11478465B2 (cg-RX-API-DMAC7.html)
EP (2) EP3886858B1 (cg-RX-API-DMAC7.html)
JP (1) JP7730816B2 (cg-RX-API-DMAC7.html)
CN (1) CN114845718B (cg-RX-API-DMAC7.html)
AU (1) AU2020408179B2 (cg-RX-API-DMAC7.html)
BR (1) BR112022009192A2 (cg-RX-API-DMAC7.html)
CA (1) CA3157394A1 (cg-RX-API-DMAC7.html)
DK (1) DK3886858T3 (cg-RX-API-DMAC7.html)
ES (1) ES2921360T3 (cg-RX-API-DMAC7.html)
IL (1) IL293469B2 (cg-RX-API-DMAC7.html)
MX (1) MX2022006439A (cg-RX-API-DMAC7.html)
PL (1) PL3886858T3 (cg-RX-API-DMAC7.html)
WO (1) WO2021123142A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202204939B (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
CA3157394A1 (en) * 2019-12-19 2021-06-24 Helena ERIKSSON Compounds for treatment of eye diseases associated with excessive vascularisation
AU2022248724A1 (en) 2021-04-01 2023-11-02 Active Biotech Ab Laquinimod formulation for ocular use
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
EP4734995A1 (en) * 2023-06-28 2026-05-06 Board of Regents, The University of Texas System Quinoline carboxamides for use in the treatment of mpn
CN117256554A (zh) * 2023-09-08 2023-12-22 益诺思生物技术南通有限公司 一种c57bl/6j小鼠新生血管型眼病模型及其构建方法
KR102925647B1 (ko) * 2023-10-13 2026-02-11 재단법인 대구경북첨단의료산업진흥재단 안질환 치료제

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077851A (en) 1998-04-27 2000-06-20 Active Biotech Ab Quinoline derivatives
SE9801474D0 (sv) * 1998-04-27 1998-04-27 Active Biotech Ab Quinoline Derivatives
US6875869B2 (en) 2002-06-12 2005-04-05 Active Biotech Ab Process for the manufacture of quinoline derivatives
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
WO2010070449A2 (en) 2008-12-17 2010-06-24 Actavis Group Ptc Ehf Highly pure laquinimod or a pharmaceutically acceptable salt thereof
AU2011274496B2 (en) * 2010-07-09 2016-03-10 Teva Pharmaceutical Industries Ltd. Deuterated N-ethyl-N-phenyl-1,2-dihydro-4-hydroxy-5-chloro-1-methyl-2-oxoquinoline-3-carboxamide, salts and uses thereof
EP2463289A1 (en) 2010-11-26 2012-06-13 Almirall, S.A. Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors
EP2527344A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases
EP2537517A1 (en) * 2011-06-22 2012-12-26 Active Biotech AB Deuterium-enriched 4-hydroxy-5-methoxy-n,1-dimethyl-2-oxo-n-[(4-trifluoro-methyl)phenyl]-1,2-dihydroquinoline-3-carboxamide
SG10201606191PA (en) 2011-07-28 2016-09-29 Teva Pharma Treatment of multiple sclerosis with combination of laquinimod and glatiramer acetate
EP2844268A4 (en) * 2012-04-20 2015-11-25 Univ Howard METHOD FOR THE TREATMENT OF EYE DISEASE AND COMPOSITIONS FOR THE TREATMENT OF EYE DISEASE
WO2013173307A1 (en) * 2012-05-16 2013-11-21 Neil Desai Multi-target modulation for treating fibrosis and inflammatory conditions
TW201400117A (zh) * 2012-06-05 2014-01-01 Teva Pharma 使用拉喹莫德治療眼發炎疾病
AU2013342275B2 (en) * 2012-11-08 2017-11-09 Clearside Biomedical, Inc. Methods and devices for the treatment of ocular diseases in human subjects
CN105163730B (zh) * 2013-01-08 2018-10-30 帕萨罗杰卡有限公司 用于治疗脱髓鞘疾病的方法和组合物
BR112016000177A2 (pt) * 2013-07-11 2017-12-12 Novartis Ag usos de um antagonista do vegf no tratamento de doenças neovasculares coriorretinianas e de permeabilidade em pacientes pediátricos, seringa pré-cheia, kit e formulação de liberação lenta
WO2015060812A1 (en) 2013-10-21 2015-04-30 Howard University Treating ocular disease with efflux transporter inhibitors
WO2015073697A1 (en) * 2013-11-15 2015-05-21 Teva Pharmaceutical Industries Ltd. Treatment of glaucoma using laquinimod
EP3082761A2 (en) * 2013-12-20 2016-10-26 Emory University Formulations and methods for targeted ocular delivery of therapeutic agents
WO2017120355A1 (en) 2016-01-06 2017-07-13 Teva Pharmaceutical Industries Ltd. Dihydroquinolines and uses thereof
CN108778330A (zh) * 2016-01-08 2018-11-09 科尼尔赛德生物医学公司 用阿柏西普和其他生物制品治疗后眼部障碍的方法和装置
US10905770B2 (en) * 2017-07-17 2021-02-02 Macregen, Inc. Topical delivery of therapeutic agents using cell-penetrating peptides for the treatment of age-related macular degeneration and other eye diseases
MA51327A (fr) 2017-12-22 2021-05-26 Chemocentryx Inc Composés cycliques fusionnés en 5,5 à substitution diaryle, utilisés en tant qu'inhibiteurs du c5ar
MX2020006459A (es) 2017-12-22 2020-11-06 Chemocentryx Inc Compuestos de anillos fusionados 6,5 diaril sustituidos como inhibidores de c5ar.
ES2993034T3 (en) 2018-04-02 2024-12-20 Chemocentryx Inc Prodrugs of fused-bicyclic c5ar antagonists
CA3157394A1 (en) * 2019-12-19 2021-06-24 Helena ERIKSSON Compounds for treatment of eye diseases associated with excessive vascularisation

Similar Documents

Publication Publication Date Title
US11951103B2 (en) Pharmaceutical composition
JP2017514917A5 (cg-RX-API-DMAC7.html)
FI4364724T3 (fi) Korkean pitoisuuden VEGF-reseptorifuusioproteiinia sisältäviä formulaatioita
JP2020530470A5 (cg-RX-API-DMAC7.html)
JP2023506838A5 (cg-RX-API-DMAC7.html)
JP2021535112A5 (cg-RX-API-DMAC7.html)
JP2022081661A5 (cg-RX-API-DMAC7.html)
JP2017503835A5 (cg-RX-API-DMAC7.html)
CN108135737A (zh) 用于治疗翼状胬肉的组合物和方法
JP2019510078A5 (cg-RX-API-DMAC7.html)
JP7730816B2 (ja) 過剰血管新生に関連する眼疾患を治療する化合物
US20110142923A1 (en) Ophthalmic pharmaceutical compositions for the treatment of neoangiogenic pathologies of the eye
JP2021522180A5 (cg-RX-API-DMAC7.html)
JP2013510852A5 (cg-RX-API-DMAC7.html)
WO2017002941A1 (ja) クエン酸エステルを含有するデポ剤
JP7470791B2 (ja) 眼疾患の予防または治療用点眼組成物
RU2017112930A (ru) Офтальмологические составы для доставки лекарств и защиты переднего отдела глаза
JP2017527600A5 (cg-RX-API-DMAC7.html)
CN111683682A (zh) 用于预防或治疗伴有眼内血管新生和/或眼内血管通透性亢进的眼科疾病的药物
CN113227086B (zh) 作为用于治疗神经视网膜疾病的视网膜前体细胞的生产的刺激剂的n-(4-(噁唑-5-基)苯基)色满-3-甲酰胺衍生物及相关化合物
JP2019534269A5 (cg-RX-API-DMAC7.html)
RU2019114205A (ru) Способы лечения глазного заболевания с применением ингибиторов csf-1r
JP2021138710A5 (cg-RX-API-DMAC7.html)
JP2022520832A5 (cg-RX-API-DMAC7.html)
WO2010117077A1 (ja) シロリムス誘導体を有効成分として含有する網脈絡膜疾患の治療剤